Chronic Lymphocytic Leukemia | Specialty

Dr Jain on Current Challenges in Defining Venetoclax Failure in CLL

May 21st 2025

Dr Winter on the Role of Treatment History in Richter Transformation

May 19th 2025

Allison Winter, MD, emphasizes the importance of carefully evaluating treatment history in patients with Richter transformation from CLL.

Five Under 5: Top Oncology Videos for the Week of 5/11

May 18th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Dr Bhat on Using BTK Degraders and Bispecific Antibodies to Address Challenges With R/R CLL Management

May 16th 2025

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Dr Bhat on the Limitations of Current Treatments for Double-Refractory CLL

May 12th 2025

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Patients With Progressive CLL After Zanubrutinib or Ibrutinib Therapy Often Do Not Have BTK-Mutated Disease

May 11th 2025

BTK mutations occurred at low rates in patients with CLL who had disease progression after receiving zanubrutinib or ibrutinib in the phase 3 ALPINE study.

Patient Symptoms and Disease Features Guide Pirtobrutinib Use in R/R CLL

May 9th 2025

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Dr Shadman on the Utility of a Meta Analysis of BTK Inhibitors in R/R CLL

April 30th 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

Acalabrutinib/Venetoclax With or Without Obinutuzumab Earns Positive CHMP Opinion for Untreated CLL

April 29th 2025

The EMA’s CHMP has recommended the approval for acalabrutinib/venetoclax with or without obinutuzumab in untreated CLL.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Dr Cortese on Potential Mechanisms for Improving CLL Outcomes With Venetoclax

April 25th 2025

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

Orelabrutinib Wins Approval in China for First-Line CLL and SLL

April 25th 2025

China’s NMPA has approved orelabrutinib for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

Meta Analysis Shows Efficacy Trend Favoring Zanubrutinib in High-Risk R/R CLL

April 24th 2025

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Dr Shadman on the Framework of a Meta Analysis of BTK Inhibitors in R/R CLL

April 21st 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Dr Hernandez-Ilizaliturri on Studying Immunologic Changes With Venetoclax in CLL

April 18th 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies

April 18th 2025

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

MRD-Guided Zanubrutinib/Venetoclax/Obinutuzumab Triplet Induces Deep Remissions in R/R CLL

April 16th 2025

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

Dr Opat on the Unique Mechanism of Action of Sonrotoclax in R/R CLL

April 16th 2025

Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.

Dr Ghia on the Role of Fixed-Duration Ibrutinib Plus Venetoclax in CLL and Beyond

April 14th 2025

Paolo Ghia, MD, PhD, discusses ongoing and future directions for the investigation of fixed-duration ibrutinib/venetoclax in CLL.